Despite what many people think, the pandemic isn't officially over yet. And while the world has made tremendous progress, the coronavirus continues to cause problems. COVID-19 cases and hospitalizations have been on the rise in the U.S., which once again highlights the importance of effective vaccines and medicines against the disease.

Among the companies that have developed vaccines for COVID-19 are the two biotechs (NASDAQ: NVAX) and BioNTech (NASDAQ: BNTX). Both have underperformed the broader market over the past year, but both are now surging as the COVID threat shows it's still alive and well.

But should you add shares of Novavax or BioNTech to your portfolio? Let's find out.

Continue reading

Source Fool.com